Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab
Tawfek, A., Elgharieb, M., Alnahass, H., Alnahrawy, O., Gab-Alla, A. (2022). Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab. EKB Journal Management System, 25(2), 7-11. doi: 10.21608/scumj.2022.223251
Ahmed Z. Tawfek; Mervat E. Elgharieb; Hussein S. Alnahass; Osama M. Alnahrawy; Amr A. Gab-Alla. "Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab". EKB Journal Management System, 25, 2, 2022, 7-11. doi: 10.21608/scumj.2022.223251
Tawfek, A., Elgharieb, M., Alnahass, H., Alnahrawy, O., Gab-Alla, A. (2022). 'Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab', EKB Journal Management System, 25(2), pp. 7-11. doi: 10.21608/scumj.2022.223251
Tawfek, A., Elgharieb, M., Alnahass, H., Alnahrawy, O., Gab-Alla, A. Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab. EKB Journal Management System, 2022; 25(2): 7-11. doi: 10.21608/scumj.2022.223251

Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab

Suez Canal University Medical Journal
Article 2, Volume 25, Issue 2, July 2022, Page 7-11  XML PDF (207.66 K)
Document Type: Original Article
DOI: 10.21608/scumj.2022.223251
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Z. Tawfek email ; Mervat E. Elgharieb; Hussein S. Alnahass; Osama M. Alnahrawy; Amr A. Gab-Alla
Department of Ophthalmology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Abstract
Background: Diabetic macular edema is a general term defined as retinal thickening within two-disc diameters of the foveal center; it can be either focal or diffuse in distribution.Intravitreal injection of anti-vascular endothelial growth factor (Ranibizumab) was approved for the treatment of diabetic macular edema. Objective:Assessment of correlation between diabetic cystoid macular edema and best-corrected visual acuity (BCVA) after intravitreal injection of Ranibizumab. Patients and Methods: Quasi-experimental interventional study was undertaken at Suez Canal University Hospital, Ophthalmology Department on patients who were diagnosed as having diabetic cystoid macular edema (CME) by optical coherence topography. A total of 60 participants were evaluated by taking a complete ophthalmologic history, examination, and investigations using a pre-designed checklist, and intravitreal injection of anti-VEGF was done. Results: Our study showed that the study group consisted of 71.4% females and 28.3% males. In our study group, we found that the Mean ± SD. In CME 3.50 ± 0.50 pre-VEGF injection, 2.0 ± 0.82 post VEGF injection with improvement1.50±0.50 (44.44%). The mean of BCVA in decimal among participants was 0.15 ± 0.06 pre-VEGF injection while 0.25 ± 0.07 post-VEGF injection with an improvement of 0.10 ± 0.03 (25.0%). There was strong relation and statistically significant. Conclusion: Intravitreal injection of anti-VEGF was very effective in diabetic macular edema. Improvement of diabetic macular edema was associated with improvement in best-corrected visual acuity.
 
Keywords
Anti-VEGF; CME; BCVA; Optical coherence tomography (OCT)
Statistics
Article View: 173
PDF Download: 215